MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI, USA.
Journla of Immunotherapy (Impact Factor: 3.35). 10/2007; 30(7):675-83. DOI: 10.1097/CJI.0b013e3180de4d19
Source: PubMed

ABSTRACT One focus in the field of tumor immunology is the identification of cancer-specific antigens that might be exploited as therapeutic targets or as immunologic diagnostic markers. Cancer-testis antigens (CTAs) are of particular interest as potential target antigens given that their expression is typically restricted to germ cells among normal tissues, but aberrantly expressed in multiple tumor types. In the current report, we sought to evaluate serum antibody immune responses to a defined panel of CTA from multiple antigen families to identify potential tumor-specific antigens that could potentially serve as candidate target antigens for immunotherapy or diagnostic purposes. This was conducted by screening sera from male patients with metastatic melanoma (n=44) and volunteer blood donors (n=50) against a panel of lambda phage-encoded CTA. We found that IgG antibody responses occurred in 39% of patients with melanoma to at least one of these antigens compared with 4% of controls (P<0.001). We found antibody responses to one antigen, MAD-CT-2, occurred in 27% of patients compared with 0/50 controls (P<0.0001). These findings, along with the demonstration that MAD-CT-2 is expressed in melanoma cell lines, identified MAD-CT-2 as a novel melanoma CTA.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Membrane antigens are critical to the pathogenesis of chronic lymphocytic leukemia (CLL) as they facilitate microenvironment homing, proliferation, and survival. Targeting the CLL membrane and associated signaling patterns is a current focus of therapeutic development. Many tumor membrane targets are simultaneously targeted by humoral immunity, thus forming recognizable immunoglobulin responses. We sought to utilize this immune response to identify novel membrane-associated targets for CLL. Using a novel strategy we interrogated CLL membrane-specific autologous IgG reactivity. Our analysis unveiled Lymphocyte Cytosolic Protein 1 (LCP1), a lymphocyte-specific target which is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. siRNA knockdown of LCP1 blocked migration towards CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. Furthermore, we demonstrate that the BTK inhibitor ibrutinib or the PI3K inhibitor idelalisib block B-cell receptor induced activation of LCP1. Our data demonstrate a novel strategy to identify cancer membrane target antigens using humoral anti-tumor immunity. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance. This clinical trial is registered at Study ID number: OSU-0025 OSU-0156.
    Blood 09/2013; · 9.78 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Immunotherapeutic strategies have been limited by the lack of known tumor restricted antigens and inadequate immune responses. In our Institution, an ongoing Phase I dose escalation study in 11 high risk MDS patients, who failed hypo-methylating agents, were enrolled in a K562-GMCSF-CD40 ligand transfected "bystander" vaccine, in combination with lenalidomide, and have shown promising responses. Wilm's Tumor protein 1 (WT1) and Cancer Testis Antigens (CTAs) are solid candidates for future immunotherapy and vaccines containing these antigens are currently under development in solid and hematological malignancies. The K562 cell-line expresses both WT1 and numerous CTAs, the resultant immunization with this cellular vaccine is attractive for both immunological response and assessment. Here we describe immunological correlative studies before and after vaccination. Methods: We monitored the humoral response, of the four responders, to CTAs by SEREX High Throughput Immunoblot assay (HTI), 29 CTAs were bound in a concise pattern to nitrocellulose filters and developed in the following methodology. Patient sera were incubated with the HTI filters and any CTA specific antibodies bound to respective antigens and reactive antibodies were detected by secondary anti-human antibodies in a colorimetric assay. Filters were read by 6 blinded individuals, spots were scored positive or negative against control antigens. These results were compared to the paired post-therapy sample a score of 6 was maximal change of pre to post. Those CTAs with strong antibody presence post-therapy were then confirmed via ELISA resulting in an antibody titer reflected as ug/mL. A standardization of human IgG, as well as a healthy donor control was used to determine the validity of identified responses. An assessment of cellular immune responses was performed via interferon gamma (IFN{gamma}) ELISPOT and a flow based peptide and lysate specific proliferation assay, using CD8+, CD137+ and CSFE, towards WT1 peptides and K562 lysates. Results: Of the 15 patients enrolled 4 had relevant clinical responses by IWG, 2 complete responses (CR), 1 marrow CR and 1 partial response. Upon initial examination of HTI filters, 4 patients who showed clinical response were observed to have increased serum antibody responses to multiple CTAs (10 of 29) at end of therapy or last evaluable date. Response to NY-SAR-35, MAGE family, NY-ESO1 and SSX2 had the strongest post-therapy signal confirmed via ELISA. RT-PCR of bone marrow aspirates revealed a range of 5 to 9 CTA mRNA transcripts present in responsive patients at baseline which subsequently decreased to a range of 1 to 5 at post-therapy. Increased (IFN{gamma}) production was observed via elispot in an initial screening of a patient with clinical response at post-vaccination. IFN{gamma} responsive cell number was increased independent to macrophage loaded with K562 lysate or WT1 peptides in this patient. This patient also exhibited a CD8+CD137+ proliferative response upon incubation with WT1 peptides and K562 lysate. Conclusion: An increased humoral response against CTAs was seen in patients with high risk MDS after treatment with a combination of lenalidomide and K562-GM-CSF-CD40L vaccine. A majority of these CTAs were expressed by the vaccine and the patients before treatment. Interestingly, some antigens, MAGE-A4 and SSX1 as examples, exhibited low antibody responses at baseline and elevated levels at post therapy but, mRNA transcripts were conversely correlated suggesting a possible immune response. Preliminary analysis demonstrated increased specific cellular responses to WT1 peptides or K562 lysates. Further analysis of the remaining responding patients will be presented.
    American Society of Hematology Annual Meeting 2011; 11/2011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Almost 100 years ago, Ehrlich and coworkers observed the presence of infiltrates of mononuclear cells around or inside tumor lesions [1]. This finding led them to propose that tumors could be recognized and inhibited by the ‘magic bullets’ of the immune system. At the end of the 19th century, studies were initiated that aimed at actively immunizing cancer patients against their own cancerous tissue. During the subsequent decades, cancer patients were nonspecifically immune-stimulated with relatively crude leukocyte extracts such as transfer factor, immune- RNA, bacterial extracts such as bacillus Calmette- Guerain, Coley’s toxin or levamisole. These studies were initiated in spite of the fact that little was known about the various components of the immune system that could react against cancer, and even less was known about the structures on cancer cells that can be recognized by the immune system.